ImmunoGen, Inc. Earns Milestone Payment with Genentech, Inc.'s Start of Trastuzumab-DM1 (T-DM1) Phase III Clinical Testing; Other T-DM1 Progress Reported

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced several favorable developments related to T-DM1. T-DM1 comprises ImmunoGen’s DM1 cell-killing agent linked to Genentech’s anti-HER2 antibody, trastuzumab, and is in development by Genentech (US) and Roche (ex-US).